Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma

Licata, Anita; Wilson, Lynn D.; Braverman, Irwin M.; Feldman, Andrea M.; Kacinski, Barry M.

doi:10.1001/archderm.1995.01690160060009

Cited by 57 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PUVA does have a proliferative effect on melanocytes as well as immunosuppressive effects that could contribute to the development of melanoma 11 . Similarly, another study found that MF patients treated with total skin electron beam therapy have 5 times the lifetime risk of developing melanoma of that of the general population 6 …”

Section: Discussionmentioning

confidence: 99%

“…In these cases, some of the same pathologic links as those put forward to explain the increased incidence of nonmelanoma skin cancers in MF have been postulated, including effects of therapies for MF. Melanoma has been reported in several MF patients treated with PUVA therapy 2,4,6 . While PUVA increases the risk of nonmelanoma skin cancers, its association with malignant melanoma has not been definitively demonstrated 11 .…”

Section: Discussionmentioning

confidence: 99%

“…Patients with MF have a higher frequency (6-16%) of second malignancies than the general population 1 but only 12 cases of patients with both MF and melanoma have been reported. [2][3][4][5][6] A pathologic link has been suggested in these patients. We report six cases of MF associated with melanoma and one case associated with dysplastic nevus syndrome (DNS).…”

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome

2003

View full text Add to dashboard Cite

There is an elevated prevalence of malignant melanoma in MF patients compared to the general US population (P < 0.00001) with a relative risk of 15.3 for observing malignant melanoma in MF patients (95% confidence interval 7.0-33.8). Possible pathologic links between the two diagnoses include effects of mycosis fungoides therapies, immunosuppression secondary to mycosis fungoides, and genetic alterations in the p16 tumor suppressor protein.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome

2003

View full text Add to dashboard Cite

show abstract

“…Elevated risk for lung cancer and melanoma of the skin was associated with ultraviolet (UV) exposure and altered immunity. Depressed immunity has been documented in some patients with cutaneous T‐cell lymphoma (CTCL) who have not received treatment 5 . Diminished monocyte chemotaxis and increased proportions of suppressor T cells have been reported in patients with active CTCL.…”

mentioning

confidence: 99%

“…The increased risk of the lung and colon cancers, NHL, and squamous cell carcinoma (SCC) and melanoma of the skin was reported after CTCL 6–8 . Oral psoralen with UVA phototherapy, increasingly employed to treat early stage CTCL, also has been associated with the development of non‐melanoma skin cancers 5,9 …”

mentioning

confidence: 99%

Occurrence of angiosarcoma and gastric adenocarcinoma following a cutaneous CD30-positive anaplastic large cell lymphoma

Kang¹,

Chang²,

Choi³

et al. 2002

Br J Dermatol

View full text Add to dashboard Cite

Second Lymphomas and Other Malignant Neoplasms in Patients With Mycosis Fungoides and Sézary Syndrome

Huang¹,

Weinstock²,

Clarke³

et al. 2007

Arch Dermatol

View full text Add to dashboard Cite

Setting: Nine population-based US cancer registries that constitute the Surveillance, Epidemiology, and End Results Program (SEER-9), and Stanford University referral center cohort of patients with cutaneous lymphoma.Patients: Patients with mycosis fungoides or Sézary syndrome from the SEER-9 registry diagnosed and followed up from 1984 through 2001 and from the Stanford University cohort diagnosed and followed up from 1973 through 2001.Main Outcome Measures: Relative risk was estimated using the standardized incidence ratio (SIR). The expected cancer incidence for both cohorts was calculated using age-, sex-, race-, and calendar year-specific SEER-9 incidence rates for the general population. Nonmelanoma skin cancers were excluded because these cancers are not routinely reported by the SEER database. Results: In the SEER-9 cohort (n = 1798), there were 197 second instances of cancer (SIR=1.32; 95% confidence interval [CI], 1.15-1.52) at all sites. Significantly elevated risk (PϽ.01) was observed for Hodgkin disease (6 cases; SIR = 17.14; 95% CI, 6.25-37.26) and non-Hodgkin lymphoma (27 cases; SIR=5.08; 95% CI, 3.34-7.38). Elevated risk (PϽ.05) was also observed for melanoma (10 cases; SIR = 2.60; 95% CI, 1.25-4.79), and urinary cancer (21 cases; SIR=1.74; 95% CI, 1.08-2.66). In the Stanford University cohort (n=429), there were 37 second instances of cancer (SIR=1.04; 95% CI, 0.76-1.44). Elevated risk (PϽ.01) was observed for Hodgkin disease (3 cases; SIR = 27.27; 95% CI, 5.35-77.54). Elevated risk (PϽ.05) was also observed for biliary cancer (2 cases; SIR = 11.76; 95% CI, 1.51-42.02). Conclusion: Updated SEER (population based) and Stanford (clinic based) data confirm the generalizability of earlier findings of increased risk of lymphoma in patients with mycosis fungoides or Sézary syndrome.

show abstract

Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma

Cited by 57 publications

References 30 publications

Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome

Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome

Occurrence of angiosarcoma and gastric adenocarcinoma following a cutaneous CD30-positive anaplastic large cell lymphoma

Second Lymphomas and Other Malignant Neoplasms in Patients With Mycosis Fungoides and Sézary Syndrome

Contact Info

Product

Resources

About